Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
B-cell malignancies are a heterogeneous subset of non-Hodgkin lymphomas in which treatment has remained essentially unchanged for the past 3 decades.
BTK Inhibitors: Real-World Insights on Patient Management and Therapy Selection
Nathan H. Fowler, MD, discusses the use of BTK inhibitors in B-cell malignancies.
The Changing Treatment Landscape in MCL and CLL: A Review of Standards of Care
Among the many new developments in B-cell lymphoma in recent years, the inhibition of Bruton tyrosine kinase represents a particularly notable achievement.
Dr Phillips on the Treatment Landscape for Patients With MCL
Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
2 Commerce Drive Cranbury, NJ 08512